Education
About Us
Working with TipRanks
Follow Us
Pluri (PLUR)
NASDAQ:PLUR
PLUR Stock Chart & Stats
$3.45
-$0.22(-4.74%)
At close: 4:00 PM EST
$3.45
-$0.22(-4.74%)
Day’s Range― - ―
52-Week Range$3.02 - $7.13
Previous CloseN/A
Volume1.48K
Average Volume (3M)8.39K
Market Cap
$27.44M
Enterprise Value$43.10M
Total Cash (Recent Filing)$15.06M
Total Debt (Recent Filing)$34.24M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Feb 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding9,253,897
10 Day Avg. Volume13,380
30 Day Avg. Volume8,388
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)-45.85
Price to Sales (P/S)234.79
P/FCF Ratio-15.82
Enterprise Value/Market Cap1.57
Enterprise Value/Revenue32.50
Enterprise Value/Gross Profit75.75
Enterprise Value/Ebitda-1.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pluri News
PLUR FAQ
What was Pluri’s price range in the past 12 months?
Pluri lowest stock price was $3.02 and its highest was $7.13 in the past 12 months.
What is Pluri’s market cap?
Pluri’s market cap is $27.44M.
When is Pluri’s upcoming earnings report date?
Pluri’s upcoming earnings report date is Feb 11, 2025 which is 312 days ago.
How were Pluri’s earnings last quarter?
Currently, no data Available
Is Pluri overvalued?
According to Wall Street analysts Pluri’s price is currently Overvalued.
Does Pluri pay dividends?
Pluri does not currently pay dividends.
What is Pluri’s EPS estimate?
Pluri’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pluri have?
Pluri has 9,253,897 shares outstanding.
What happened to Pluri’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pluri?
Currently, no hedge funds are holding shares in PLUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pluri
Pluri (PLUR) is a biotechnology company focused on developing innovative therapies based on its proprietary technology platform for cell reprogramming and stem cell biology. Operating primarily in the healthcare and life sciences sectors, Pluri specializes in creating novel treatments for various diseases, particularly in regenerative medicine and immunotherapy. The company aims to harness the potential of pluripotent stem cells to address unmet medical needs and improve patient outcomes through advanced cellular therapies.
Technical Analysis
IGC Pharma
―
Iterum Therapeutics
―
PolyPid
―
AN2 Therapeutics, Inc.
―
Mural Oncology Plc
―
Ownership Overview
34.73% Insiders
0.03% Mutual Funds
0.13% Other Institutional Investors
64.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---